Impact of Oxygen Therapy on Fatigue in Patients With Hypermobile-type Ehlers-Danlos Syndrome

Sponsor
Hospital St. Joseph, Marseille, France (Other)
Overall Status
Recruiting
CT.gov ID
NCT04890431
Collaborator
(none)
82
3
2
21.7
27.3
1.3

Study Details

Study Description

Brief Summary

The hypothesis of the OXYSED study is that the delivery of 3 months of oxygen therapy via an oxygen concentrator would reduce fatigue, pain, headaches, kinesiophobia, drug intake, dyspnea, and improve walking performance, quality of sleep and quality of life of patients with Ehlers Danlos syndrome hypermobility type (EDS / HT).

Condition or Disease Intervention/Treatment Phase
Phase 4

Study Design

Study Type:
Interventional
Anticipated Enrollment :
82 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
Impact of Oxygen Therapy on Fatigue in Patients With Hypermobile-type Ehlers-Danlos Syndrome: a Randomised Double-blind Placebo-controlled Study
Actual Study Start Date :
Mar 10, 2022
Anticipated Primary Completion Date :
Oct 1, 2023
Anticipated Study Completion Date :
Jan 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Oxygen

Drug: Oxygen
oxygen treatment (5 L/minute for 30 minutes by nasal cannula, twice/day)

Placebo Comparator: Placebo

Drug: Placebo
ambient air not enriched with oxygen (5 L/minute for 30 minutes by nasal cannula, twice/day)

Outcome Measures

Primary Outcome Measures

  1. FSS (Fatigue Severity Scale) score [7 months]

  2. FSS (Fatigue Severity Scale) score [10 months]

Secondary Outcome Measures

  1. PRISM (Pictorial Representation of Illness and Self Measure) score [7 and 10 months]

  2. SF-36 quality of life questionnaire (Short Form Heath Survey) score [7 and 10 months]

  3. TSK (Tampa Scale Kinesiophobia) score [7 and 10 months]

  4. walk test results [7 and 10 months]

  5. HIT-6 (Headache Impact Test) score [7 and 10 months]

  6. NQ (Nijmegen questionnaire ) score [7 and 10 months]

  7. Epworth Sleepiness score [7 and 10 months]

  8. PSQI (Pittsburgh sleep quality index) score [7 and 10 months]

  9. HADS (Hospital Anxiety and Depression Scale) score [7 and 10 months]

  10. NYHA (New Year Heart Association) score [7 and 10 months]

  11. consumption of care [7 and 10 months]

    The consumption of care is defined by the presence of at least one major criterion associated or not with the minor criterion: Major criteria: Variation of at least one level in the frequency of use and / or in the duration of use compared to the baseline assessment concerning the use of flexible and / or rigid orthoses, Variation of at least one level of the analgesic levels used compared to the baseline assessment for pain relievers. Variation of at least one level in frequency compared to the baseline assessment for physiotherapy sessions. Minor criterion: Variation of the total daily dose compared to the baseline assessment for painkillers.

  12. Number of oxygen therapy sessions followed by the patient [7 and 10 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Aged ≥ 18 years;

  • Diagnosed with EDS/HT defined by the New York critieria;

  • With intense fatigue defined by an FSS ≥ 4;

  • Having given free and informed written consent;

  • Speaking french language;

  • Being affiliated with or benefiting from a social security scheme.

Exclusion Criteria:
  • with progressive parenchymal pulmonary pathology (pulmonary fibrosis, post-smoking emphysema);

  • having an ongoing pregnancy or breastfeeding;

  • who have already received oxygen therapy for the EDS / HT indication in the last 6 months;

  • having a pathology that causes fatigue, which is not compensated or treated; non-exhaustive list anemia, sleep apnea syndrome, psychiatric pathologies including severe depression, organ failure (cardiac, renal, respiratory, hepatic), endocrinopathies (hypo or hyperthyroidism, diabetes), nutritional deficiencies;

  • Subject to a measure for the protection of justice.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hopital Raymond Poincaré Garches France
2 Clinique de la Mitterie Lille France
3 Hopital Saint Joseph Marseille France

Sponsors and Collaborators

  • Hospital St. Joseph, Marseille, France

Investigators

  • Principal Investigator: Boris Bienvenu, Hopital Saint Joseph Marseille

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hospital St. Joseph, Marseille, France
ClinicalTrials.gov Identifier:
NCT04890431
Other Study ID Numbers:
  • OXYSED
First Posted:
May 18, 2021
Last Update Posted:
Mar 31, 2022
Last Verified:
Mar 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 31, 2022